Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement to acquire the ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) business of Sanofi in an all-cash transaction with a total value of up to $125 million, consisting of $97.5 million upfront and up to $27.5 million in near-term contingent regulatory and manufacturing-related milestones.
{iframe}https://globenewswire.com/news-release/2017/07/14/1047013/0/en/Emergent-BioSolutions-to-Acquire-ACAM2000-Business-From-Sanofi.html{/iframe}